International Neuropsychiatric Disease Journal

Background: Optogenetics combines genetic targeting with light-sensitive proteins to manipulate cellular activity with high temporal precision. It has become an important method for investigating neural circuits and mechanisms relevant to neurodegenerative disorders.

Objective: This narrative review examines the molecular basis of light-gated ion channels and related opsins, their contribution to causal circuit analysis, disease-oriented applications, and barriers to clinical translation. Methods: Topic-focused searches of the literature were used to identify foundational experimental studies and selected peer-reviewed reviews on microbial opsins, neural-circuit research, neurodegenerative disorders and translational considerations. This was not a systematic review; no exhaustive screening, formal risk-of-bias assessment or meta-analysis was undertaken.

Discussion: Excitatory and inhibitory opsins enable researchers to test how defined neuronal populations and activity patterns influence memory, movement and pathological network dynamics. Alzheimer’s disease research has examined memory-associated circuits and gamma-frequency activity, while Parkinson’s disease studies have clarified contributions of basal-ganglia pathways to motor behaviours. Evidence is less extensive and more heterogeneous for Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. Findings from cellular and animal models support mechanistic investigation but do not establish clinical efficacy. Direct therapeutic translation faces challenges involving gene delivery, cell specificity, optical access, device compatibility, immune responses and long-term safety. Indirect translation—using circuit knowledge to inform established neuromodulation or other interventions—may be more feasible for some disorders.

Conclusion: Optogenetics is best regarded as a powerful research platform and a source of therapeutic hypotheses, rather than an established treatment for most neurodegenerative diseases. Progress will depend on reproducible disease-relevant outcomes, rigorous safety assessment and clinically meaningful evaluation.